+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Frontiers of Clinical Research in Type 1 Diabetes

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Type 1 diabetes may appear at any age. The onset may be insidious and even asymptomatic for a long time. The prediabetic stage is characterized by genetic susceptibility, the presence of autoantibodies in serum, and gradual impairment of the β-cell function. HLA-DQ-encoded heterodimers are strongly associated with increased risk/protection. Additional diabetogenic genes are present in other chromosomes, different from HLA region genes. Screening of prediabetes is usually restricted to first-degree relatives of type 1 diabetic subjects. Islet cell antibody (ICA)-positive gestational diabetic women form a subset of patients with increased risk of developing type 1 diabetes shortly after pregnancy. Optimization of metabolic control is the key strategy for preventing late diabetic complications. Diabetic education, intensive insulin therapy and regular screening for early detection are critical in achieving this goal. Individual monitoring of subjects at high risk for developing hypoglycaemias, and development of more adequate short- and long-acting insulin analogues represent important measures to avoid hypoglycaemia and associated risks. Effective delivery of care for type 1 diabetic subjects requires the operation of a continuous quality assessment programme.

          Related collections

          Author and article information

          Horm Res Paediatr
          Hormone Research in Paediatrics
          S. Karger AG
          10 December 2008
          : 45
          : Suppl 1
          : 32-35
          Department of Endocrinology, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma, Barcelona, Spain
          184826 Horm Res 1996;45:32–35
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Symposium II: Insulin-Dependent Diabetes Mellitus


          Comment on this article